Skip to main content

Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.

Publication ,  Journal Article
Peters, WP; Rosner, G; Ross, M; Vredenburgh, J; Meisenberg, B; Gilbert, C; Kurtzberg, J
Published in: Blood
April 1, 1993

Two hematopoietic colony-stimulating factors, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF), have been shown to accelerate leukocyte and neutrophil recovery after high-dose chemotherapy and autologous bone marrow (BM) support. Despite their use, a prolonged period of absolute leukopenia persists during which infections and other complications of transplantation occur. We collected large numbers of peripheral blood (PB) progenitors after CSF administration using either G-CSF or GM-CSF and tested their ability to affect hematopoietic reconstitution and resource utilization in patients undergoing high-dose chemotherapy and autologous BM support. Patients with breast cancer or melanoma undergoing high-dose chemotherapy and autologous BM support were studied in sequential nonrandomized trials. After identical high-dose chemotherapy, patients received either BM alone, with no CSF; BM with either G-CSF or GM-CSF; or BM with G-CSF or GM-CSF and G-CSF or GM-CSF primed peripheral blood progenitor cells (PBPC). Hematopoietic reconstitution, as well as resource utilization, was monitored in these patients. The use of CSF-primed PBPC led to a highly significant reduction in the duration of leukopenia with a white blood cell (WBC) count under 100 and 200 cells/mL, and neutrophil count under 100 and 200 cells/mL with both GM- and G-CSF primed PB progenitor cells, compared with the use of the CSF with BM or with historical controls using BM alone. In addition, the use of CSF-primed PBPC resulted in a significant reduction in median number of antibiotics used, days in the Bone Marrow Transplant Unit, and hospital resources used. Patients receiving G-CSF primed PBPC also experienced a reduction in the median number of days in the hospital, red blood cell (RBC) transfusions, platelet transfusions, days on antibiotics, and discounted hospital charges. Phenotypic analysis of the CSF-primed PBPC indicated the presence of cells bearing antigens associated with both early and late hematopoietic progenitor cells. The use of CSF-primed PBPC can significantly improve hematopoietic recovery after high-dose chemotherapy and autologous BM support. In addition, the use of G-CSF-primed PBPC was associated with a significant reduction in hospital resource utilization, and a reduction in hospital charges.

Duke Scholars

Published In

Blood

ISSN

0006-4971

Publication Date

April 1, 1993

Volume

81

Issue

7

Start / End Page

1709 / 1719

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Middle Aged
  • Immunology
  • Humans
  • Hematopoietic Stem Cells
  • Hematopoietic Stem Cell Transplantation
  • Hematopoiesis
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Granulocyte Colony-Stimulating Factor
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM

Published In

Blood

ISSN

0006-4971

Publication Date

April 1, 1993

Volume

81

Issue

7

Start / End Page

1709 / 1719

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Middle Aged
  • Immunology
  • Humans
  • Hematopoietic Stem Cells
  • Hematopoietic Stem Cell Transplantation
  • Hematopoiesis
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Granulocyte Colony-Stimulating Factor
  • Combined Modality Therapy